The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Insights into Methotrexate Toxicity in Elderly Patients with Rheumatic Disease

Insights into Methotrexate Toxicity in Elderly Patients with Rheumatic Disease

December 12, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2022—For patients with moderate to severe rheumatoid arthritis (RA) disease activity, methotrexate monotherapy is recommended when initiating treatment with a disease-modifying anti-rheumatic drug (DMARD). Methotrexate, a dihydrofolate reductase inhibitor immunosuppressant, is preferred over other agents, such as Janus kinase inhibitors, because of its established safety and efficacy as a first-line DMARD and its low cost.1

You Might Also Like
  • 7 Insights into Methotrexate Administration, Drug Resistance & Toxicity
  • 2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA
  • RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
Also By This Author
  • FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA

Although the use of low-dose methotrexate to treat rheumatic conditions is usually safe, it sometimes causes life-threatening events. A study by Martin Aringer, MD, Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, and colleagues examined severe cases of methotrexate toxicity for outcome, presentation and associated risk factors.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Methods

The investigators identified patients with rheumatic diseases and severe methotrexate toxicity between 2011 and 2020. Using electronic health records, they collected patient data on age, sex, diagnosis, methotrexate dose, methotrexate duration of treatment, concomitant medication(s), toxicity symptoms, infections and patient outcome. The estimated glomerular filtration rate (eGFR), an indication of renal function, was assessed before methotrexate toxicity occurred, at admission to the hospital, during hospitalization and at hospital discharge. Additionally, data from a group of 150 patients with RA who were 70 years of age and older were analyzed for comparison.

Results

In the study, 11 patients—four men and seven women—aged 71–88 years were admitted to the hospital for severe methotrexate toxicity. Of these patients, seven had RA, two had giant cell arteritis, one had psoriasis and one had psoriatic arthritis. When admitted, all 11 patients had severe mucositis, eight patients had pancytopenia, 10 patients had renal impairment and six patients had skin lesions (not defined). Five patients had septicemia, and four patients had pulmonary infiltrates.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One patient died from complications related to septicemia. Nine patients were discharged from the hospital after an average of 26 days. The 11th patient’s outcome was not reported.

Two patients had recently started methotrexate. In the remaining eight patients, methotrexate had been used for a mean of 5.8 years (range: 3 months to 20 years). The last dose of methotrexate prescribed was a weekly dose of 13.3 mg ± 3.5 mg (mean ± SD), ranging from 7.5–20 mg. Plasma methotrexate levels were detectable in four of nine patients (range: 0.02–0.10 µmol/L). An accidental methotrexate overdose was clinically suspected in one patient.

Concomitant medications included non-steroidal anti-inflammatory drugs (NSAIDs), such as COX-2 inhibitors (n=4) and angiotensin receptor blockers (ARBs; n=4); angiotensin-converting enzyme inhibitors (ACEi; n=2); and diuretics (n=5). Two patients took a combination of NSAIDs, ARBs or ACEi and diuretics.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: ACR Convergence 2022, Methotrexate, Rheumatoid Arthritis (RA), toxicity

You Might Also Like:
  • 7 Insights into Methotrexate Administration, Drug Resistance & Toxicity
  • 2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA
  • RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
  • Upadacitinib + Methotrexate & Other csDMARDs in RA Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)